Total IP	105
Total IP Rank #	12,288
IP Activity Score	2.9/5.0    118
IP Activity Rank #	5,843
Stock Symbol	PRLD (nasdaq)
ISIN	US74065P1012
Market Cap.	116M  (USD)
Dominant Nice Class	Scientific, technological and in...

Patents Trademarks 42 2 13 2 44 2 0
Last Patent	2024 - Cdk inhibitors and their use as ...
First Patent	2017 - Selective inhibitors of protein ...
Last Trademark	2019 - PRELUDE THERAPEUTICS
First Trademark	2019 - PRELUDE THERAPEUTICS

Industry (Nice Classification)

Latest Inventions, Goods, Services 2024 Invention Cdk inhibitors and their use as pharmaceuticals. The disclosure is directed to compounds of Form... 2023 Invention Brm targeting compounds and associated methods of use. The present disclosure provides bifunctio... Invention Brm targeting compounds and associated methods of use. The present disclosure provides bifunction... Invention Mutant pi3k-alpha inhibitors and their use as pharmaceuticals. The disclosure is directed to comp... Invention Cdk inhibitors and their use as pharmaceuticals. The disclosure is directed to compounds of Formu... Invention Treatment of cancers using combinations of smarca2 degraders and kras targeting therapies. Method... Invention Brm targeting compounds and associated methods of use. The disclosure is directed to compounds o... Invention Brm targeting compounds and associated methods of use. The disclosure is directed to compounds of... Invention Kat6 targeting compounds. The present disclosure provides bifunctional compounds comprising a ta... Invention Kat6 targeting compounds with ubiquitin ligase binding moiety. The present disclosure provides bi... Invention Processes for making prmt5 inhibitors. The disclosure provides processes for preparing the compou... Invention 6,6a,7,8,9,10-hexahydro-5h-pyrazino[1',2':4,5]pyrazino[2,3-c]pyridazine derivatives as smarca4 pr... Invention Cdk inhibitors and their use as pharmaceuticals. The disclosure is directed to, in part, to CDK ... Invention Mutant pi3k-alpha inhibitors and their use as pharmaceuticals. The disclosure is directed to com... Invention Thaizole-pyrimdiine cdk inhibitors and their use as pharmaceuticals. The disclosure is directed t... 2022 Invention Substituted pyrrolo[2,3-d]pyrimidines as inhibitors of protein arginine methyl transferase 5 (prm... Invention Crystalline forms of a substituted benzimidazole acting as as cdk9 inhibitor and uses thereof. Th... Invention Cdk inhibitors and their use as pharmaceuticals. The disclosure is directed to, in part, to CDK i... Invention Polymorphic compounds and uses thereof. The present invention provides freebase and salt forms us... 2021 Invention Processes for making prmt5 inhibitors. The disclosure provides processes for preparing the compo... Invention Selective inhibitors of protein arginine methytransterase 5 (prmt5). The disclosure is directed ... Invention Heterocycle cdk inhibitors and their use thereof. The disclosure is directed to, in part, to het... Invention Spiro-sulfonamide derivatives as inhibitors of myeloid cell leukemia-1 (mcl-1) protein. The disc... Invention Spiro-sulfonimidamide derivatives as inhibitors of myeloid cell leukemia-1 (mcl-1) protein. The ... 2020 Invention Selective inhibitors of protein arginine methyltransferase 5 (prmt5). The disclosure is directed... Invention Selective inhibitor of protein arginine methyltransferase 5 (prmt5). The disclosure is directed ... 2019 G/S Research and development of drugs in the fields of oncology, hematology, autoimmune diseases, and... G/S Research and development of drugs in the fields of oncology, hematology, autoimmune diseases, an...